These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9439900)

  • 21. Role of Inflammatory and Oxidative Stress, Cytochrome P450 2E1, and Bile Acid Disturbance in Rat Liver Injury Induced by Isoniazid and Lipopolysaccharide Cotreatment.
    Hassan HM; Guo H; Yousef BA; Guerram M; Hamdi AM; Zhang L; Jiang Z
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5285-93. PubMed ID: 27324775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
    Bouazzi OE; Hammi S; Bourkadi JE; Tebaa A; Tanani DS; Soulaymani-Bencheikh R; Badrane N; Bengueddour R
    Pan Afr Med J; 2016; 25():167. PubMed ID: 28292129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
    Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
    Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress.
    Boelsterli UA; Lee KK
    J Gastroenterol Hepatol; 2014 Apr; 29(4):678-87. PubMed ID: 24783247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antituberculosis drug-induced hepatitis: risk factors, prevention and management.
    Hussain Z; Kar P; Husain SA
    Indian J Exp Biol; 2003 Nov; 41(11):1226-32. PubMed ID: 15332488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
    Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
    Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents.
    Bourré-Tessier J; Arino-Torregrosa M; Choquette D
    Clin Rheumatol; 2014 Aug; 33(8):1049-53. PubMed ID: 24554383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isoniazid-induced acute hepatitis and acute pancreatitis in a patient during chemoprophylaxis.
    Jin CF; Sable R
    J Clin Gastroenterol; 2002 Jul; 35(1):100-1. PubMed ID: 12080238
    [No Abstract]   [Full Text] [Related]  

  • 29. [Hepatotoxicity caused by isoniazid or by paracetamol].
    Andrade RJ; Lucena MI; Melgarejo F; García-Escaño MD
    Gastroenterol Hepatol; 1998; 21(6):314-5. PubMed ID: 9711017
    [No Abstract]   [Full Text] [Related]  

  • 30. IgG3 is the dominant subtype of anti-isoniazid antibodies in patients with isoniazid-induced liver failure.
    Metushi IG; Lee WM; Uetrecht J
    Chem Res Toxicol; 2014 May; 27(5):738-40. PubMed ID: 24786179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isoniazid hepatotoxicity requiring liver transplantation.
    Sheen E; Huang RJ; Uribe LA; Nguyen MH
    Dig Dis Sci; 2014 Jul; 59(7):1370-4. PubMed ID: 24573717
    [No Abstract]   [Full Text] [Related]  

  • 32. [Severe hepatotoxicity of tuberculostatic agents. Increase in the incidence].
    Moitinho E; Salmerón JM; Mas A; Bruguera M; Rodés J
    Gastroenterol Hepatol; 1996 Nov; 19(9):448-51. PubMed ID: 8998667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
    Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
    Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isoniazid hepatotoxicity in renal transplant recipients.
    Antony SJ; Ynares C; Dummer JS
    Clin Transplant; 1997 Feb; 11(1):34-7. PubMed ID: 9067692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
    Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
    Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Tuberculosis: relevance of isoniazid dosage in prevention of liver side effects].
    Negri L; Le Grusse J; Séraissol P; Lavit M; Houin G; Gandia P
    Therapie; 2014; 69(6):509-16. PubMed ID: 25314930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antituberculosis drugs and hepatotoxicity.
    Yew WW; Leung CC
    Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of isoniazid-induced hepatotoxicity: then and now.
    Metushi I; Uetrecht J; Phillips E
    Br J Clin Pharmacol; 2016 Jun; 81(6):1030-6. PubMed ID: 26773235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(8):224-9. PubMed ID: 20203555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?
    Cojutti P; Duranti S; Isola M; Baraldo M; Viale P; Bassetti M; Pea F
    J Antimicrob Chemother; 2016 May; 71(5):1323-9. PubMed ID: 26832752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.